Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aqua 2020!
Cheers!
Thumbs up!
Cheers!
Cheers!
Have a Merry Christmas to the Elite family!
Cheers!
Have a Merry Christmas to the Amarin family!
Cheers!
Looks good, guys!
Cheers!
Cheers!
I never left the building.
Cheers!
2020 might be an Elite year. Also, it is the year of the Rat or Nas-“Rat” Hakim.
Cheers!
A good day to say, “Cheers!”.
Cheers!
Hooray! Got me some shares
Cheers!
Bought some. Cheers!
How’s AMBS doing? Looking to buy shares
4-cents is a steal.
Cheers!
Cheers!
No way, Aqua is on top!
Cheers!
Aqua never left the building.
Mele Kalikimaka and Cheers!
An FDA-approval would make Elite great!
Cheers!
Cheers!
Wow, who bought shares?
Cheers!
As an educated investor, that decision to buy/sell rests solely on the individual investor. Having the discipline to follow one's set of investment rules and not give in to one's emotions creates the opportunities to profit.
Cheers!
My best advice is to only buy ELTP on discount due to the risky nature of the OTC market and the unpredictability of the FDA. It's either a hit or miss. ELTP is made for the risk tolerant investors. Others should move on.
Cheers!
It's not considered a lost until Nasarat sells.
Cheers!
Today's news is not in any way, shape, or form in comparison to the time when the FDA recalled Lodrane-24 in 2011. Elite would eventually bounce back.
Cheers!
Beware of fake news! Due diligence would win the day.
Cheers!
Sorry, no private messages. Totally agree.
Cheers!
SequestOX, alone, will not make Elite. It's the diversity of its drug pipeline that will make Elite.
Cheers!
Hakim did not rip off anyone. As investors in the OTC, we all knew the risks/rewards. Doing business with the FDA is like baseball, Elite struck out and needs to wait its turn again in the rotation. But eventually, she'll get her groove back and knock one out of the park.
Cheers!
A dime per share. Love this bargain.
Cheers!
Nice to see NO FAKE NEWS, but real growth in the company.
Cheers!
Incredible! Cheers!
Why continue to kick a dead duck? Might be a slim chance that it is still quacking.
Big Mahalos and Cheers!
Looking forward to the new CEO and her/his business plan to infuse more capital and grow the company. Unless you know who the next CEO would be, it would be reckless to assume the next CEO and his team would engage in more dilution.
Cheers!
Hmm, makes me wonder why anyone would kick a dead horse? If it is over, then why talk about a dead stock?
Cheers!
Enron was much worse. Especially if you were an employee that invested their life savings in the company shares. If you do a search for the Enron ticker symbol, it has been delisted. However, a search KMA Global shows that it is still listed. There is still hope for KMAG despite being in the gray market.
Cheers!
C H E E R $ !
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017 and Provides Conference Call Information
Conference Call Scheduled for Thursday, June 15 at 2:00 PM EDT
NORTHVALE, N.J., June 14, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the fiscal year ended March 31, 2017 ("Fiscal 2017").
Consolidated revenues for Fiscal 2017 were $9.6 million, a decrease of approximately 23% as compared to revenues for the prior year. The prior year's revenues including a non-recurring $2.5 million milestone related to the development of SequestOx™ offset strong growth in Elite's generic sales. A decrease in methadone contract manufacturing also contributed to a decrease in revenues. Product development activities continued to accelerate during Fiscal 2017, which resulted in the achievement of several significant milestones. These milestones included filing ANDA applications for generic versions of Percocet and Norco, receiving positive topline results for the first product Elite is jointly developing with SunGen Pharma, and acquiring an ANDA for generic Trimipramine, which will be marketed by Dr. Reddy's Laboratories.
"It was a good year for Elite. We now have three filed ANDAs under active review by the FDA and have recently purchased an already approved ANDA," commented Nasrat Hakim, Elite's President and CEO. "We look forward to approvals, product launches and the growth which they will generate. We are excited about the next fiscal year as Elite continues to fill its pipeline with additional ANDA filings and approvals."
Conference Call Information
Elite's management will host a conference call to discuss the year end 2017 financial results and provide an update on recent business developments. Stockholder questions should be summited to the company in advance of the call.
Date: Thursday, June 15, 2017
Time: 2:00 PM EDT
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com by 9:00 AM EDT on Thursday, June 15, 2017
Audio Replay: http://ir.elitepharma.com/events_presentations
The financial statements can be viewed for Elite's Fiscal Year-end Report on Form 10-K here.
Cheers!
We could be in for some big gains. I can't believe we have just only started.
Cheers!
AMG acquires control share of Solos. A step in the right direction.
Cheers!
Cheers!